$9.31
0.010.11%
At close: Jul 17, 7:44 PM EDT
$9.32
0.01000.11%
After Hours: 7:44 PM EDT
15 minutes delayed
Comments
Loading...
Summit Therapeutics
SMMTNASDAQ
Summit Therapeutics (NASDAQ:SMMT) Stock, Analyst Ratings, Price Targets, Forecasts
Summit Therapeutics Inc has a consensus price target of $13.5 based on the ratings of 2 analysts. The high is $14 issued by Stifel on June 3, 2024. The low is $13 issued by Citigroup on May 31, 2024. The 3 most-recent analyst ratings were released by Stifel, Citigroup, and Citigroup on June 3, 2024, May 31, 2024, and May 7, 2024, respectively. With an average price target of $11.33 between Stifel, Citigroup, and Citigroup, there's an implied 21.60% upside for Summit Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Citigroup
1calculated from analyst ratings
Analyst Ratings for Summit Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 50.21% | Stifel | Bradley Canino | $8 → $14 | Maintains | Buy | Get Alert |
| 05/31/2024 | Buy Now | 39.48% | Citigroup | Yigal Nochomovitz | $7 → $13 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | -24.89% | Citigroup | Yigal Nochomovitz | → $7 | Initiates | → Buy | Get Alert |
| 03/26/2024 | Buy Now | -14.16% | Stifel | Bradley Canino | → $8 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Summit Therapeutics (SMMT) stock?
The latest price target for Summit Therapeutics (NASDAQ:SMMT) was reported by Stifel on June 3, 2024. The analyst firm set a price target for $14.00 expecting SMMT to rise to within 12 months (a possible 50.21% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Summit Therapeutics (SMMT)?
The latest analyst rating for Summit Therapeutics (NASDAQ:SMMT) was provided by Stifel, and Summit Therapeutics maintained their buy rating.
When was the last upgrade for Summit Therapeutics (SMMT)?
There is no last upgrade for Summit Therapeutics
When was the last downgrade for Summit Therapeutics (SMMT)?
There is no last downgrade for Summit Therapeutics.
When is the next analyst rating going to be posted or updated for Summit Therapeutics (SMMT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Summit Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Summit Therapeutics was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Summit Therapeutics (SMMT) correct?
While ratings are subjective and will change, the latest Summit Therapeutics (SMMT) rating was a maintained with a price target of $8.00 to $14.00. The current price Summit Therapeutics (SMMT) is trading at is $9.32, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.